MedTrace Logo

Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon

NCT02683408 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2017-08-17

No results posted yet for this study

Summary

Diosmiplex is a product marketed for the management of diseases due to venous and microvascular dysfunction. Raynaud's phenomenon is a disorder of characterized by spasm of small arteries and impaired microvascular flow. This study will examine the effects of diosmiplex on the frequency and severity of Raynaud's episodes in susceptible people.

Conditions

  • Raynaud's Disease

Interventions

OTHER

placebo

inactive placebo

DIETARY_SUPPLEMENT

diosmiplex

diosmiplex is an FDA regulated medical food product

Sponsors & Collaborators

  • Primus Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Robert Levy, MD · Primus Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02683408 on ClinicalTrials.gov